Gliptin versus a sulphonylurea as add-on to metformin

被引：26

作者：

Scheen, Andre J. ^{[1
]}

Paquot, Nicolas

机构：

[1] Univ Liege, Div Diabet Nutr & Metab Disorders, B-4000 Liege, Belgium

来源：

LANCET | 2012年 / 380卷 / 9840期

关键词：

TYPE-2; EFFICACY; VILDAGLIPTIN; MANAGEMENT; GLIPIZIDE; 52-WEEK; SAFETY; 2-YEAR;

D O I：

10.1016/S0140-6736(12)60859-9

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

收藏

页码：450 / 452

页数：3

相关论文

共 14 条

[1]

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial [J].

Arechavaleta, R. ;

Seck, T. ;

Chen, Y. ;

Krobot, K. J. ;

O'Neill, E. A. ;

Duran, L. ;

Kaufman, K. D. ;

Williams-Herman, D. ;

Goldstein, B. J. .

DIABETES OBESITY & METABOLISM, 2011, 13 (02) :160-168

[2]

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies [J].

Elashoff, Michael ;

Matveyenko, Aleksey V. ;

Gier, Belinda ;

Elashoff, Robert ;

Butler, Peter C. .

GASTROENTEROLOGY, 2011, 141 (01) :150-156

[3]

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study [J].

Filozof, C. ;

Gautier, J. -F. .

DIABETIC MEDICINE, 2010, 27 (03) :318-326

[4]

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial [J].

Gallwitz, Baptist ;

Rosenstock, Julio ;

Rauch, Thomas ;

Bhattacharya, Sudipta ;

Patel, Sanjay ;

von Eynatten, Maximilian ;

Dugi, Klaus A. ;

Woerle, Hans-Juergen .

LANCET, 2012, 380 (9840) :475-483

[5]

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial [J].

Goke, B. ;

Gallwitz, B. ;

Eriksson, J. ;

Hellqvist, A. ;

Gause-Nilsson, I. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (12) :1619-1631

[6]

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis [J].

Goossen, K. ;

Graeber, S. .

DIABETES OBESITY & METABOLISM, 2012, 14 (12) :1061-1072

[7]

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J].

Inzucchi, S. E. ;

Bergenstal, R. M. ;

Buse, J. B. ;

Diamant, M. ;

Ferrannini, E. ;

Nauck, M. ;

Peters, A. L. ;

Tsapas, A. ;

Wender, R. ;

Matthews, D. R. .

DIABETOLOGIA, 2012, 55 (06) :1577-1596

[8]

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study [J].

Matthews, D. R. ;

Dejager, S. ;

Ahren, B. ;

Fonseca, V. ;

Ferrannini, E. ;

Couturier, A. ;

Foley, J. E. ;

Zinman, B. .

DIABETES OBESITY & METABOLISM, 2010, 12 (09) :780-789

[9]

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials [J].

Scheen, A. J. .

DIABETES & METABOLISM, 2012, 38 (02) :89-101

[10]

Exenatide once weekly in type 2 diabetes [J].

Scheen, Andre J. .

LANCET, 2008, 372 (9645) :1197-1198